Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement.

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

A bill introduced by Republicans in the Minnesota state legislature calls mRNA vaccines "weapons of mass destruction" and if ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

SK bioscience won a patent case against Moderna in Korea, impacting mRNA technology development and potential vaccine exports ...

SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...